Business
Appointment of the Interim CEO to the Board
SkinBioTherapeutics plc has appointed Rachel Parsonage as a director to the Board, serving as Interim CEO, following the completion of regulatory due diligence by the Company's Nominated Adviser. Parsonage, aged 51, currently holds no shareholding in SkinBioTherapeutics and has a background in leading consumer beauty and wellness companies, including previous roles at KMI Brands and This Works. The company is awaiting the outcome of an external investigation and preparing for its HY results, with further announcements expected in due course. Disclaimer*
About this update from Skinbiotherapeutics Plc
[{"type":"text","content":"\n\n\n \nSkinBioTherapeutics plc\n(\"SkinBioTherapeutics\" or \"the Company\" or the \"Group\")\n \nAppointment of the Interim CEO to the SBTX Board of Directors\n \n9 March 2026 - SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, has confirmed the appointment of Rachel Parsonage, Interim CEO to the Board of Directors. Her appointment was subject to normal regulatory due diligence carried out by the Company's Nominated Adviser, which is now complete.\n \nMartin Hunt, Executive Chairman of SkinBioTherapeutics, said:\n\"Rachel has been in the post of Interim CEO for just a week so far, and already, she has met the majority of the team and is getting under the skin of the business, including building relationships with our key partners. Her deep experience in leading consumer beauty and wellness companies is evident in her approach, and she has a clear plan of what she wants to achieve in the immediate near term. In the meantime, we are waiting for the outcome of the external investigation as well as preparing for the HY results. We will make further announcements on these events in due course.\" \n-Ends-\n \nThe following information is disclosed pursuant to rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies:\n \n\n\n\n\nFull name:\n\n\nRachel Parsonage\n\n\n\n\nAge:\n\n\n51\n\n\n\n\nShareholding in SkinBioTherapeutics:\n\n\nNil\n\n\n\n\nCurrent directorships held:\n\n\nAlera Advisory Ltd\n\n\n\n\nDirectorships held in the previous 5 years:\n\n\nKnowledge & Merchandising Inc Ltd\nKMI Brands Ltd\nKMI Brands Inc\n\n\n\n\nDirectorships or Shadow Directorships held in companies that have entered administration or insolvency:\n\n\nThis Works Limited [Dissolved 20 April 2011]\nKnowledge and Merchandising Intellectual Property Limited [Voluntarily dissolved 27 December 2011]\nEnormous Yes Company Limited\n[Voluntarily dissolved 9 February 2016]\nILK Limited\n[Voluntarily dissolved 2021 and went into administration on 30 June 2023]\n\n\n\n\n \nThumbnail image\n\nInterim CEO, Rachel Parsonage\n \nFor more information please contact:\n\n\n\n\nSkinBioTherapeutics plc Martin Hunt, Executive Chairman\nEmily Bertram, CFO\n\n\[email protected]\n \n\n\n\n\nSinger Capital Markets (Nominated Adviser & Broker)\nPhilip Davies\...